A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors

Abstract Background Several programmed cell death ligand 1 (PD‐L1)/programmed cell death protein 1 (PD‐1) antibodies have been approved for cancer treatment worldwide. Their pharmacokinetic and pharmacodynamic characteristics have been reported mainly in western countries, but related data in Chines...

Full description

Bibliographic Details
Main Authors: Xiao‐Li Wei, Chao Ren, Feng‐Hua Wang, Yang Zhang, Hong‐Yun Zhao, Ben‐Yan Zou, Zhi‐Qiang Wang, Miao‐Zhen Qiu, Dong‐Sheng Zhang, Hui‐Yan Luo, Feng Wang, Sheng Yao, Rui‐Hua Xu
Format: Article
Language:English
Published: Wiley 2020-08-01
Series:Cancer Communications
Subjects:
anti‐PD‐1 antibody
toripalimab
phase I study
safety
efficacy
pharmacokinetics
Online Access:https://doi.org/10.1002/cac2.12068

Internet

https://doi.org/10.1002/cac2.12068

Similar Items